Edition:
United States

Reata Pharmaceuticals Inc (RETA.OQ)

RETA.OQ on NASDAQ Stock Exchange Global Market

25.10USD
15 Dec 2017
Change (% chg)

$0.27 (+1.09%)
Prev Close
$24.83
Open
$24.92
Day's High
$25.46
Day's Low
$24.90
Volume
379,959
Avg. Vol
65,638
52-wk High
$40.56
52-wk Low
$19.85

Chart for

About

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical... (more)

Overall

Beta: --
Market Cap(Mil.): $655.47
Shares Outstanding(Mil.): 26.11
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko

* REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK)

Dec 07 2017

BRIEF-Reata Pharmaceuticals files for offering of up to $50.0 million of shares of Class A common stock‍​

* Files for offering of up to $50.0 million of shares of Class A common stock‍​ - SEC filing Source text : (http://bit.ly/2AG2XNP) Further company coverage:

Nov 13 2017

BRIEF-Reata Pharmaceuticals Q3 loss per share $0.50

* Reata Pharmaceuticals Inc announces third quarter 2017 financial and operating results

Nov 13 2017

BRIEF-Reata Pharmaceuticals enters first amendment to loan and security agreement​

* Reata Pharmaceuticals says ‍on November 3, co entered into a first amendment to loan and security agreement​ - SEC filing

Nov 07 2017

BRIEF-Reata provides update on Bardoxolone Methyl from American Society of Nephrology Kidney Week Meeting

* Reata provides update on bardoxolone methyl from the american society of nephrology kidney week meeting

Nov 06 2017

BRIEF-Reata Pharmaceuticals says top-line data to be available in 2019 for omaveloxolone​

* Reata Pharmaceuticals Inc - ‍announces first patient enrolled in Part 2 of Moxie study of omaveloxolone for treatment of Friedreich's Ataxia​

Oct 23 2017

BRIEF-Reata Pharma receives orphan drug designation for Omaveloxolone

* Reata Pharmaceuticals Inc receives orphan drug designation for Omaveloxolone for the treatment of malignant melanoma

Sep 13 2017

BRIEF-Reata Pharmaceuticals Q2 loss per share $0.52

* Reata pharmaceuticals Inc announces second quarter 2017 financial and operating results

Aug 14 2017

BRIEF-Reata announces first patient enrolled in Phase 3 Cardinal trial of Bardoxolone Methyl in the treatment of chronic kidney disease due to Alport Syndrome

* Reata announces first patient enrolled in phase 3 cardinal trial of Bardoxolone Methyl in the treatment of chronic kidney disease due to Alport Syndrome Source text for Eikon: Further company coverage:

Aug 07 2017

BRIEF-William Rose reports 15.4 percent stake in Reata Pharmaceuticals Inc as on Aug 1

* William Rose reports 15.4 percent stake in Reata Pharmaceuticals Inc as on Aug 1 - SEC filing‍​

Aug 02 2017

Earnings vs. Estimates